VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
T-1101 (Tosylate)
Phase 1
Small molecule
T
Taivex Therapeutics Corporation
1
Indications
3
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Advanced Refractory Solid Tumors
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Advanced Refractory Solid Tumors
Phase 1
Completed
Clinical
Trials by Indication
[1]
Advanced Refractory Solid Tumors
3 trials
Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
Terminated
·
T
Taivex Therapeutics Corporation
·
Phase 1
·
NCT03195764
·
21 enrolled
An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
Completed
·
T
Taivex Therapeutics Corporation
·
Phase 1
·
NCT03349073
·
3 enrolled
A Phase I Study of Safety, Tolerability and Pharmacokinetics of T-1101 (Tosylate) Capsules in Subjects With Advanced Refractory Solid Tumors
Completed
·
T
Taivex Therapeutics Corporation
·
Phase 1
·
NCT04685473
·
24 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
3 trial records for T-1101 (Tosylate). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
T-1101 (Tosylate) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for T-1101 (Tosylate). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Taivex Therapeutics Corporation company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 1
[1]
Company
T
Taivex Therapeutics Corporation
Related News